Hunan Nucien Pharmaceutical Co. Ltd. Class A

As of June 30, 2026, Hunan Nucien Pharmaceutical Co. Ltd. Class A carries a market capitalization of 1.64B, placing it among publicly traded companies globally. Its enterprise value stands at 1.28B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Hunan Nucien Pharmaceutical Co. Ltd. Class A has 274.40M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Hunan Nucien Pharmaceutical Co. Ltd. Class A maintains a current ratio of 3.13, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Hunan Nucien Pharmaceutical Co. Ltd. Class A recorded 17.04M in income tax expense.

As of the close on October 22, 2026, Hunan Nucien Pharmaceutical Co. Ltd. Class A's stock has declined approximately 30.54% over the past 52 weeks. The 50-day moving average sits at 6.54, while the 200-day moving average is 7.53.

As of June 30, 2026, Hunan Nucien Pharmaceutical Co. Ltd. Class A holds 347.18M in cash and equivalents against 60.02M in total debt, resulting in a net debt position of -287.16M. Total book value stands at 780.52M, with working capital of 300.82M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Hunan Nucien Pharmaceutical Co. Ltd. Class A's most recent stock split took place on June 13, 2023 with a 5:7 split ratio.